Anti-SARS-CoV-2 activity of small molecule inhibitors of cathepsin L
The coronavirus disease 2019(COVID-19)is an acute infectious disease caused by the new severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection,which has led to serious worldwide economic burden.Due to the continuous emergence of variants,vaccines and monoclonal antibodies are only partial effective against infections caused by distinct strains of SARS-CoV-2.Therefore,it is still of great importance to call for the development of broad-spectrum and effective small molecule drugs to combat both current and future outbreaks triggered by SARS-CoV-2.Cathepsin L(CatL)cleaves the spike glycoprotein(S)of SARS-CoV-2,playing an indispensable role in enhancing virus entry into host cells.Therefore CatL is one of the ideal targets for the development of pan-coronavirus inhibitor-based drugs.In this study,a CatL enzyme inhibitor screening model was established based on fluorescein labeled substrate.Two CatL inhibitors IMB 6290 and IMB 8014 with low cytotoxicity were obtained through high-throughput screening,the half inhibition concentrations(IC50)of which were 11.53±0.68 and 1.56±1.10 pmol·L1,respectively.SDS-PAGE and cell-cell fusion experiments confirmed that the compounds inhibited the hydrolysis of S protein by CatL in a concentration-dependent manner.Surface plasmon resonance(SPR)detection showed that both compounds exhibited moderate binding affinity with CatL.Molecular docking revealed the binding mode between the compound and the CatL active pocket.The pseudovirus experiment further confirmed the inhibitory effects of IMB 8014 on the S protein mediated entry process.In vitro pharmacokinetic evaluation indicated that the compounds had relatively good drug-likeness properties.Our research suggested that these two compounds have the potential to be further developed as antiviral drugs for COVID-19 treatment.
万方数据
维普
